Clinical Trials | March 23, 2024
AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer
Combination shows consistent benefit across prespecified post-progression outcomes
Combination shows consistent benefit across prespecified post-progression outcomes
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol
To accelerate the development of next-generation radioconjugates to treat cancer
The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value
A five-day inspection was concluded successfully with no critical and no major observations raised
Additional capacity broadens Grace’s fine chemical capabilities for API production
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Subscribe To Our Newsletter & Stay Updated
